EOLS icon

Evolus

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 83.3%
Negative

Neutral
Business Wire
4 days ago
Evolus to Participate in The Leerink Partners Global Healthcare Conference
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in a fireside chat and investor meetings at the upcoming Leerink Partners Global Healthcare Conference in Miami, FL. The fireside chat will take place on Wednesday, March 11, 2026, at 11:20 AM ET. The fireside chat can be accessed on the Investor Relations page of the.
Evolus to Participate in The Leerink Partners Global Healthcare Conference
Neutral
Zacks Investment Research
5 days ago
Evolus, Inc. (EOLS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Evolus (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Evolus, Inc. (EOLS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Neutral
Business Wire
12 days ago
Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its fourth quarter and full-year 2025 financial results on Tuesday, March 3, 2026, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's.
Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026
Neutral
Business Wire
16 days ago
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio, today reported the grant during December 2025, January 2026, and February 2026 of an aggregate of 153,218 restricted stock units (RSUs) and 34,952 stock options of the company's common stock to 36 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under.
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neutral
Business Wire
1 month ago
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio, today announced its preliminary, unaudited net revenue for the fourth quarter and full-year ended December 31, 2025. The preliminary unaudited results described in this press release are based on the most current information available to management and are subject to change until the audit of the company's 2025 financial results is completed a.
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue
Positive
Seeking Alpha
2 months ago
AMG Frontier Small Cap Growth Fund: Q3 Sees Strong Outperformance Across Semiconductor Holdings
Our portfolios underperformed during the quarter and trail year to date. Health care was the primary hindrance as a result of our underweight in biotech and negative stock selection. We have materially decreased our position as we evaluate this specific risk.
AMG Frontier Small Cap Growth Fund: Q3 Sees Strong Outperformance Across Semiconductor Holdings
Neutral
Business Wire
3 months ago
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in November of non-qualified stock options to purchase an aggregate of 17,871 shares of Evolus and an aggregate of 45,063 restricted stock units (RSUs) of the company's common stock to 13 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the compan.
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neutral
Seeking Alpha
3 months ago
Evolus, Inc. (EOLS) Q3 2025 Earnings Call Transcript
Evolus, Inc. ( EOLS ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Nareg Sagherian - Head of Global Investor Relations & Corporate Communications David Moatazedi - President, CEO & Director Rui Avelar - Chief Medical Officer and Head of Research & Development Tatjana Mitchell - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Alyssa Larios - Leerink Partners LLC, Research Division Navann Ty Dietschi - BNP Paribas, Research Division Uy Ear - Mizuho Securities USA LLC, Research Division Douglas Tsao - H.C. Wainwright & Co, LLC, Research Division Serge Belanger - Needham & Company, LLC, Research Division Sam Eiber - BTIG, LLC, Research Division Presentation Operator Good afternoon, everyone, and thank you for standing by.
Evolus, Inc. (EOLS) Q3 2025 Earnings Call Transcript
Neutral
Zacks Investment Research
3 months ago
Evolus, Inc. (EOLS) Reports Q3 Loss, Beats Revenue Estimates
Evolus, Inc. (EOLS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.19 per share a year ago.
Evolus, Inc. (EOLS) Reports Q3 Loss, Beats Revenue Estimates
Neutral
Business Wire
3 months ago
Evolus Reports Third Quarter 2025 Financial Results
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the third quarter ended September 30, 2025. “Our third quarter results reflect double-digit growth despite the current market environment. Our continued above market performance and disciplined expense management, create an important transition point for the company, as we continue to expec.
Evolus Reports Third Quarter 2025 Financial Results